Likewise, serum erythropoietin levels had only been determined in 40% of patients.[75] In another retrospective analysis from the United States of patient records from community oncology practices, nearly one‐third of a total of 491 evaluated patients with myelofibrosis did not receive a risk categorisation at diagnosis.[76] Consistently, we found a similar pattern in our clinical practice observations in France. The gene discussed is EPO; the disease is myelofibrosis.